What happened with MESO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Mesoblast’s main product, Ryoncil, treats children with acute graft-versus-host disease when steroid treatment does not work. It is a cell therapy made from donated bone marrow. The company sells it through its U.S. commercial operation to transplant centers, and these sales provide most of its revenue. It also receives royalties from JCR Pharmaceuticals, which sells TEMCELL in Japan for acute graft-versus-host disease in children and adults.
Ryoncil’s U.S. approval is limited to this pediatric indication. Sales depend on transplant centers adopting the treatment and government and private health payors providing reimbursement that makes its use financially workable for hospitals. Mesoblast lacks its own manufacturing capability and relies on Lonza to produce Ryoncil, with other providers handling storage and delivery under tightly controlled, extremely cold conditions.
Mesoblast is also developing treatments for chronic lower back pain, heart failure and adult acute graft-versus-host disease; these uses still require regulatory approval. The company has begun selling a product but is not yet profitable and needs additional capital to support continued development and commercialization.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Mesoblast’s results hinge chiefly on U.S. transplant centers adopting Ryoncil and Lonza supplying its manufacturing, with JCR Pharmaceuticals contributing a smaller Japanese royalty stream.
BioCardia, Inc.’s CardiAMP and CardiALLO heart-failure cell therapies compete with Mesoblast’s Revascor program, not its current Ryoncil business. BioCardia receives payments from partners for delivery-system services and products; watch its heart-failure trial progress for signs of competition facing Revascor.
BioCardia, Inc. earningsBCDA
BioCardia’s report will show whether its heart-failure cell-therapy programs are advancing, a sign of how directly they may compete with Mesoblast’s Revascor program.
Look for updates on the heart-failure trials, separately from payments by partners for delivery-system products and services. Trial progress would bring BioCardia’s therapies closer to competing for the same treatment opportunity as Revascor; partner payments without clear trial progress would offer little evidence that pressure on Mesoblast’s program is increasing.
